Literature DB >> 11736879

Distribution of R- and S-methadone into human milk during multiple, medium to high oral dosing.

E J Begg1, T J Malpas, L P Hackett, K F Ilett.   

Abstract

AIMS: To measure the interdose milk to plasma ratio (M/P) of R- and S-methadone during multiple dosing in lactating mothers taking medium to high doses of methadone (> 40 mg daily), and to assess likely infant exposure.
METHODS: Eight mother/child pairs were studied, initially during their postpartum hospital stay (immature milk), and where possible again after 15 days (mature milk). The women were on a methadone maintenance programme with daily doses of >or=40 mg day-1. Venous blood was collected at 0, 1, 2, 4, 6, 8, 12, and 24 h and milk was collected from both breasts at 0-4, 4-8, 8-12, 12-16, 16-20, and 20-24 h after dose. R- and S-methadone were quantified by h.p.l.c. The areas under the plasma and milk concentration-time curves (AUC) were estimated and M/P(AUC) was calculated. The relative infant dose of both enantiomers was estimated as the product of drug concentration in milk and an average daily milk intake of 0.15 l kg(-1).
RESULTS: For immature milk (n = 8) the M/P(AUC) for R-methadone was 0.68 (95% CI 0.48, 0.89) and for S-methadone 0.38 (0.26, 0.50). For mature milk (n = 2) the M/P(AUCs) for R-methadone were 0.39 and 0.54 and for S-methadone 0.24 and 0.30, respectively. The estimated doses of R- and S-methadone that would be received by the infant via immature milk were 3.5% (2.05, 5.03%) and 2.1% (1.3, 2.8%), respectively, of the maternal dose (assuming 50% of each enantiomer in the dose). The relative infant dose for R- plus S-methadone together was 2.8% (1.7, 3.9%).
CONCLUSIONS: Breastfeeding during medium to high dose methadone appears to be 'safe' according to conventional criteria because the dosage is < 10%. However because the absolute dose received by the infant is dependent on the maternal dose rate, the risk-benefit ratio should be considered for each individual case. The doses of methadone received via milk are unlikely to be sufficient to prevent the neonatal abstinence syndrome.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11736879      PMCID: PMC2014565          DOI: 10.1046/j.0306-5251.2001.01506.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

Review 1.  Mechanisms of fatal opioid overdose.

Authors:  J M White; R J Irvine
Journal:  Addiction       Date:  1999-07       Impact factor: 6.526

2.  Binding of d-methadone, l-methadone, and dl-methadone to proteins in plasma of healthy volunteers: role of the variants of alpha 1-acid glycoprotein.

Authors:  C B Eap; C Cuendet; P Baumann
Journal:  Clin Pharmacol Ther       Date:  1990-03       Impact factor: 6.875

3.  Enantioselective analysis of methadone in sweat as monitored by liquid chromatography/ion spray-mass spectrometry.

Authors:  P Kintz; A Tracqui; C Marzullo; A Darreye; F Tremeau; P Greth; B Ludes
Journal:  Ther Drug Monit       Date:  1998-02       Impact factor: 3.681

4.  Enantioselective high-performance liquid chromatographic method for the determination of methadone in serum using an AGP and a CN column as chiral and analytical column, respectively.

Authors:  K Kristensen; H R Angelo; T Blemmer
Journal:  J Chromatogr A       Date:  1994-04-22       Impact factor: 4.759

5.  Methadone distribution and excretion into breast milk of clients in a methadone maintenance programme.

Authors:  R E Wojnar-Horton; J H Kristensen; P Yapp; K F Ilett; L J Dusci; L P Hackett
Journal:  Br J Clin Pharmacol       Date:  1997-12       Impact factor: 4.335

6.  Neonatal abstinence syndrome following abrupt cessation of breastfeeding.

Authors:  T J Malpas; B A Darlow
Journal:  N Z Med J       Date:  1999-01-22

Review 7.  Opioid analgesics as noncompetitive N-methyl-D-aspartate (NMDA) antagonists.

Authors:  B Ebert; C Thorkildsen; S Andersen; L L Christrup; H Hjeds
Journal:  Biochem Pharmacol       Date:  1998-09-01       Impact factor: 5.858

8.  Altered methadone pharmacokinetics in methadone-maintained pregnant women.

Authors:  S M Pond; M J Kreek; T G Tong; J Raghunath; N L Benowitz
Journal:  J Pharmacol Exp Ther       Date:  1985-04       Impact factor: 4.030

9.  Stereoselective pharmacokinetics of methadone in chronic pain patients.

Authors:  K Kristensen; T Blemmer; H R Angelo; L L Christrup; N E Drenck; S N Rasmussen; P Sjøgren
Journal:  Ther Drug Monit       Date:  1996-06       Impact factor: 3.681

10.  Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception.

Authors:  E E Codd; R P Shank; J J Schupsky; R B Raffa
Journal:  J Pharmacol Exp Ther       Date:  1995-09       Impact factor: 4.030

View more
  13 in total

Review 1.  Pharmacological Management of Opioid Use Disorder in Pregnant Women.

Authors:  Christine M Wilder; Theresa Winhusen
Journal:  CNS Drugs       Date:  2015-08       Impact factor: 5.749

Review 2.  ABM clinical protocol #21: guidelines for breastfeeding and substance use or substance use disorder, revised 2015.

Authors:  Sarah Reece-Stremtan; Kathleen A Marinelli
Journal:  Breastfeed Med       Date:  2015-04       Impact factor: 1.817

3.  Transfer of escitalopram and its metabolite demethylescitalopram into breastmilk.

Authors:  Jonathan Rampono; L Peter Hackett; Judith H Kristensen; Rolland Kohan; Madhu Page-Sharp; Kenneth F Ilett
Journal:  Br J Clin Pharmacol       Date:  2006-09       Impact factor: 4.335

4.  Estimated infant exposure to enantiomer-specific methadone levels in breastmilk.

Authors:  Debra L Bogen; James M Perel; Joseph C Helsel; Barbara H Hanusa; Matthew Thompson; Katherine L Wisner
Journal:  Breastfeed Med       Date:  2011-02-24       Impact factor: 1.817

5.  Evaluation of the analgesic effect of subcutaneous methadone after cesarean section.

Authors:  Mitra Jabalameli; Forough Kalantari
Journal:  Adv Biomed Res       Date:  2014-09-23

6.  A validated liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometric method for the quantification of methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), and 2-Ethyl-5-methyl-3,3-diphenylpyroline (EMDP) in human breast milk.

Authors:  Robin E Choo; Lauren M Jansson; Karl Scheidweiler; Marilyn A Huestis
Journal:  J Anal Toxicol       Date:  2007-06       Impact factor: 3.367

7.  Lactose-free infant formula does not change outcomes of neonatal abstinence syndrome (NAS): a randomized clinical trial.

Authors:  Rajesh Pandey; Neelakanta Kanike; Mugahid Ibrahim; Namita Swarup; Dennis M Super; Sharon Groh-Wargo; Deepak Kumar
Journal:  J Perinatol       Date:  2020-08-31       Impact factor: 2.521

8.  Can methadone concentrations predict the severity of withdrawal in infants at risk of neonatal abstinence syndrome?

Authors:  C A Kuschel; L Austerberry; M Cornwell; R Couch; R S H Rowley
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2004-09       Impact factor: 5.747

9.  ABM clinical protocol #21: Guidelines for breastfeeding and the drug-dependent woman.

Authors:  Lauren M Jansson
Journal:  Breastfeed Med       Date:  2009-12       Impact factor: 1.817

10.  The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.

Authors:  W O Farid; S A Dunlop; R J Tait; G K Hulse
Journal:  Curr Neuropharmacol       Date:  2008-06       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.